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A B S T R A C T
Purpose
Hot flashes are a common problem for which effective and safe treatments are needed. The
current trial was conducted on the basis of preliminary promising data that pregabalin decreased
hot flashes.
Patients and Methods
A double-blind, placebo-controlled, randomized trial design was used to compare pregabalin at
target doses of 75 mg twice daily and 150 mg twice daily with a placebo. Hot flash frequencies and
scores (frequency times mean severity) were recorded daily during a baseline week and for six
treatment weeks. The primary end point for this study was the change-from-baseline hot flash
score during treatment week 6 between the 150 mg twice daily target pregabalin treatment and
placebo. Nonparametric Wilcoxon rank sum tests, two-sample t tests, and 2 tests were used to
compare the primary and secondary hot flash efficacy end points between pregabalin treatments
and placebo.
Results
Hot flash score changes available for 163 patients during the sixth treatment week compared with
a baseline week decreased by 50%, 65%, and 71% in the placebo, and target 75 mg twice daily
and 150 mg twice daily pregabalin arms, respectively (P  .009 and P  .007, comparing
respective pregabalin arms to the placebo arm). While some toxicities were significantly more
common in the pregabalin arms, being more evident with the higher dose, pregabalin was
generally well tolerated by most patients.
Conclusion
Pregabalin decreases hot flashes and is reasonably well tolerated. A target dose of 75 mg twice
daily is recommended. Its effects appear to be roughly comparable to what has been reported with
gabapentin and with some newer antidepressants.
J Clin Oncol 28:641-647. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Hotflashesareamajorclinicalproblem.1While they
can be treated with hormonal treatment options,
there are concerns regarding the safety of hormonal
therapyand thus efforts areongoing tofindnonhor-
monal therapies for hot flashes.
Since the beginning of this millennium, two
classes of nonhormonal medications have been
demonstrated to effectively ameliorate hot flashes.
One group consists of relatively newantidepressants
affecting serotonin and/or norepinephrine concen-
trations. Several of these agents have been studied in
placebo-controlled trials andwere found to provide
a 50% or better reduction in hot flash frequency or
score.2 The medications studied in phase III ran-
domized, placebo-controlled trials include venla-
faxine,3 desvenlafaxine,4 fluoxetine,5 citalopram,6
sertraline,7-9 and paroxetine.10,11
The second nonhormonal agent is gabapentin,
a gamma-aminobutyric acid (GABA) analog that
has been used in a variety of neurologic and psychi-
atric disorders. This agent has also been demon-
strated to be effective in controlling hot flashes. The
exact mechanism is unclear, but it may reduce nor-
adrenergic hyperactivity.12
Gabapentin was first reported to be a promis-
ing new therapy for relief of hot flashes in a case
series report.12 This was followed by two pilot trials,
again reporting promising results.13,14 Subseque-
ntly, a placebo-controlled trial in 59 postmeno-
pausal women reported that gabapentin 900 mg/d
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decreased thehot flash frequency rate by 45%and theoverall hot flash
score by 54% after 12 weeks.15 This was significantly better than the
placebo, which had decreases of 29% and 31%, respectively. Adverse
effects of gabapentin included somnolence and dizziness.
Another randomized, placebo-controlled trial of gabapentinver-
susplacebo in420womenwithbreast cancer16 reported that aplacebo
reducedhotflashscoresafter8weeksof treatmentby15%,gabapentin
100mg three timesperday reduced themby31%, andgabapentin300
mg three times per day reduced them by 46% (P  .007), further
supporting that gabapentin is an effective nonhormonal agent for the
management of hot flashes. More recently, a three-arm study com-
pared gabapentin doses of 2,400 mg/d to estrogen to a placebo in a
double-blind clinical trial.17 This trial reported that, at 12 weeks of
therapy, there were hot flash score reductions of 71%, 72%, and 54%,
respectively (P  .02, for both comparisons to the placebo arm).
Another recently published randomized double-blind trial18 demon-
strated that gabapentin 300mg three times daily decreased hot flashes
by 51% compared with a placebo reduction of 26% (P .001).
Pregabalin (Lyrica, Pfizer, New York, NY) is a newer generation
compound that appears to work better as an analgesic than does
gabapentin.19,20 Given that pregabalin’s mechanism of action is simi-
lar to that of gabapentin, it was hypothesized that it would effectively
alleviate hot flashes. One pilot trial involving eight women who were
given pregabalin and then prospectively observed supported this
claim.19 In this trial, six of the eight women noted some relief of hot
flashes; it was judged to cause excellent relief in four women. The
mean hot flash score reduction was 65%, with a median hot flash
score reduction of 90%. Pregabalin can be administered twice daily
in contrast to gabapentin, which is often given three times per day.
This added convenience in administration makes pregabalin a
more attractive option. Given the above information, it was de-
cided to formally explore the utility of pregabalin as an agent to
alleviate hot flashes. Pursuant to this, the current clinical trial
was developed.
PATIENTS AND METHODS
Patients considered for this clinical trial were adult women with bothersome
hot flashes, defined by occurrence at least 28 times per week and sufficient
severity to make the patient desire therapeutic intervention. The hot flashes
must have been present for at least 1month before study entry. Patients must
have been able to complete questionnaires by themselves or with assistance.
Patients were not allowed on trial if they were receiving antineoplastic
chemotherapy, androgens, progestogen agents, or estrogens, with the excep-
tion that vaginal estrogen was allowed if it had been used for at least 1 month
and it was planned to be continued during the 7-week study period. Patients
werenot allowed tohaveused gabapentinor pregabalin in thepast.Current or
planneduse of other agents for hot flasheswas not allowed, except stable doses
of vitamin E, soy products, and/or antidepressants, with the understanding
that the same treatments would be continued throughout the study period.
Patients could not have had a concurrent history of renal insufficiency or have
childbearing potential.
The protocol was approved per US federal guidelines, and patients
needed to provide appropriate informed written consent. Patients were strat-
ified by age (younger than age 50 years v age 50 years or older); the use of
tamoxifen, raloxifene, or an aromatase inhibitor (yes v no); the duration of
hot flashes ( 9 months v 9 months or more); and the estimated daily
frequency of hot flashes (four to nine v nine). Subsequently, patients were
randomly allocated to one of three study arms by the North Central Cancer
TreatmentGroup (NCCTG) randomizationoffice using a dynamic allocation
procedure that balanced marginal distributions of the above stratification
factors.20 These arms consisted of a placebo treatment versus target pregabalin
doses of 75mg twice daily versus pregabalin doses of 150mg twice daily.
After random assignment, but before initiation of any study treatment,
patients were asked to complete a validated daily hot flash diary for 1 week.21
On this diary, patients were to record on a daily basis the number of mild,
moderate, severe, andvery severe hotflashes.After thisweek, patients initiated
their study treatment. Patients on the lower pregabalin arm received 50mg at
bedtime for thefirstweek, then50mgtwicedaily for the secondweek, and then
75mg twice daily for fourmore weeks. Patients on the higher pregabalin arm
received 50 mg at bedtime for the first week, then 50 mg twice daily for the
secondweek, then 75mg twice daily for the thirdweek, and then 150mg twice
daily for three more weeks. Patients receiving placebo tablets, which looked
Table 1. On-Study Patient Characteristics
Characteristic
Placebo
(n  69)
Pregabalin
Total
(N  207)
75 mg
(n  69)
150 mg
(n  69)
No. % No. % No. % No. %
Age, years
18-49 13 19 15 22 16 23 44 21
 50 56 81 54 78 53 77 163 79
Race
White 61 88 66 96 66 96 193 93
Black 6 9 3 4 3 4 12 6
American Indian or Alaskan Native 1 1 0 0 0 0 1 0.5
Not reported 1 1 0 0 0 0 1 0.5
Breast cancer history 28 41 24 35 30 44 82 40
No. of hot flashes per day
4-9 40 58 39 56 39 56 118 57
10 29 42 30 44 30 44 89 43
Duration of hot flashes ( 9 months) 61 88 61 88 61 88 183 88
Concurrent aromatase inhibitor 17 25 11 16 15 22 43 21
Concurrent raloxifene 2 3 1 1 2 3 5 2
Concurrent tamoxifen 5 7 11 16 7 10 23 11
NOTE. All 2 tests between pregabalin and placebo arms were  .05.
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identical to the pregabalin tablets, were assigned to take them on the same
schedule as the patients receiving pregabalin. While taking the study medica-
tions, patients were asked to continue to fill out the daily hot flash diaries.
In addition to the hot flash diaries, patients were asked to complete a
symptom experience questionnaire at the end of each study week. This ques-
tionnaire asked patients to score, on a scale of 0 to 10 points, the following
symptoms: unwanted weight gain, sleepiness, nausea, dizziness, an undesir-
able increase in appetite, fatigue, mouth dryness, abnormal sweating, consti-
pation, blurred or double vision, trouble sleeping, coordination difficulties,
trouble concentrating, swelling of hands and/or feet, vaginal dryness or dyspa-
reunia, less thandesirable libido, and troubleachievinganorgasm. Inaddition,
to identify other potential adverse events, specific symptoms were graded by
National Cancer InstituteCommonTerminologyCriteria forAdverse Events,
version 3.0 (CTCAE, v3.0) at baseline and then by nurse phone call at the end
of weeks 1, 3, 5, and 7. These specific symptoms included limb edema, consti-
pation, dizziness, cognitive disturbance, blurred vision, and diplopia. Patients
were also asked to complete the Profile ofMood States (POMS) tool22 and the
Hot Flash Related Daily Interference Scale (HFRDIS)23 at the end of the
baseline week and at the completion of the last treatment week.
If patients developed symptoms that were felt to be related to pregabalin
and were of unacceptable severity, the pregabalin dose could be reduced to
previous dose/frequency levels or stopped at the physician’s discretion.
On study completion, including completion of all of the questionnaires,
patients were unblinded as to treatment arm. Patients choosing to stop pre-
gabalin at this time were counseled to wean themselves from it over 10 to 13
days,dependingon thedose theywere taking.For example,patients taking300
mg twice daily were instructed to decrease their dose to 150mg twice daily for
3days, then take150mgoncedaily for3days, and then take150mgeveryother
day for three doses.
Statistical Methodology
Hot flash scores were computed for each patient by combining both
severity (mild,moderate, severe, and very severe) and frequency of hot flashes
from daily hot flash diaries, averaging across each study week.21 The primary
end point for this study was the change-from-baseline hot flash score during
treatment week 6 between the 150mg twice daily target pregabalin treatment
and placebo. Secondary end points included comparison of the 75 mg twice
daily target pregabalin treatment change-from-baseline hot flash score versus
placebo, comparisons of the change-from-baseline hot flash frequencies be-
tween 150 mg twice daily target pregabalin and 75 mg twice daily target
pregabalin treatments versus placebo, and comparisons of toxicity profiles,
moods (from POMS), and the HFRDIS scores between either treatment arm
and placebo.
Depending on the variable of interest, mean (standard deviation), me-
dian (range), and frequency (percentage) were used to summarize data in a
descriptive manner. Nonparametric Wilcoxon rank sum tests, two-sample t
tests and2 tests (orFisher’s exact tests)wereused to compare theprimaryand
secondary end points between pregabalin treatments and placebo. Because of
the exploratorynatureof secondary analysis, thePvalueswerenot adjusted for
multiple comparisons. A P value less than .05%was considered as statistically
significant for the primary end point.
RESULTS
Baseline Characteristics
This study opened for accrual on June 20, 2008, and was closed
on August 21, 2008, with a final accrual of 207 patients from 19
NCCTG member sites. Baseline patient characteristics, detailed in
Table 1, were similar in the three treatment groups. Patient study flow
is illustrated in a consort diagram (Fig 1). The reasons that some
patients were not evaluable included study dropouts for toxicities
and/or other reasons and failures to complete and/or return study
diary forms.
Hot Flash Efficacy
Hot flash score and frequency changes during treatment week 6
were available for 163 (79%) of 207 patients. Hot flash frequency and
score decreases frombaseline, in terms of actual numerical values and
in terms of percent of baseline, are listed in Table 2, with applicable P
values comparing each treatment armagainst placebo.Data regarding
Patients enrolled 
(n = 207)
Cancels
(n = 6) 
Pregabalin 75mg BID
Patients enrolled
(n = 69)   
Placebo
Patients enrolled
(n = 69)   
Eligible patients
(n = 63) 
Available for 
primary analysis
(n = 56)
Cancels
(n = 3) 
Cancels
(n = 7) 
Pregabalin 150 mg BID
Patients enrolled
(n = 69)  
Eligible patients
(n = 66) 
Eligible patients
(n = 62) 
Available for 
primary analysis
(n = 56)
Available for 
primary analysis
(n = 51)
Fig 1. CONSORT diagram. BID, twice per day.
Table 2. Median Percent and Numerical Changes in Hot Flash Scores and Frequencies During Treatment Week 6, From Baseline
Measure
Changes From Baseline to Week 6
Placebo
Pregabalin
P
75 mg Twice a Day 150 mg Twice a Day
% 95% CI % 95% CI % 95% CI
75 mg Twice
a Day v
Placebo
150 mg Twice
a Day v
Placebo
Hot flash frequency changes 36.3 51.6 to 20.3 58.5 74.6 to 48.8 61.1 72.3 to 48.3 .007 .007
Hot flash score changes 50.1 64.5 to 28.3 64.9 83.6 to 57.8 71.0 78.2 to 60.6 .009 .007
Numerical Numerical Numerical
Hot flash frequency changes 2.9 3.6 to 1.4 4.6 5.6 to 3.9 4.9 6.1 to 4.0 .003 .005
Hot flash score changes 6.1 7.9 to 2.9 9.7 12.1 to 7.3 9.6 12.9 to 7.6 .002 .007
Pregabalin for Hot Flashes
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median hot flash score and frequency changes over time are shown in
Figure 2. Percent reductions in hot flash scores and frequencies were
similarly efficacious in women grouped by whether they had 10 or
more hot flashes per day versus four to nine hot flashes per day, a
history of breast cancer versus not, and whether they were receiving
antiestrogen therapy versus not.
Information from the HFRDIS revealed that there were im-
provements at 6 weeks compared with the baseline week for the
pregabalin arms compared with the placebo arm.More specifically,
the pregabalin 75 mg twice daily target arm patients had improved
mood (P  .01) and relations with others (P  .04), while the pre-
gabalin 150 mg twice daily target arm patients recorded improve-
ments in social activities (P .04), sleep (P .001), mood (P .01),
enjoyment of life (P .05), and overall quality of life (P .02).
With regards to thePOMS, therewasno significant change in the
total POMS scores for either of the individual pregabalin arms versus
the placebo arm. For the subscales of the POMS, there was an im-
provement in the anger-hostility subscale compared with the placebo
arm for both the 75 mg twice daily target (P .006) and the 150 mg
twice daily target (P .002) pregabalin arms.
Toxicity
Toxicity differences between study arms are listed in Table 3, as
measured by CTCAE v3.0 and also by the symptom experience diary
described in Patients andMethods. For CTCAE-determined toxicity,
there wasmore dizziness with both pregabalin arms andmore cogni-
tive difficulties with the higher-dose arm compared with the placebo
arm. Toxicity information from the symptom experience diary re-
vealed significantlymore toxicity inoneorbothof thepregabalinarms
for undesirable weight gain, sleepiness, dizziness, coordination diffi-
culties, trouble concentrating, and concerns regarding blurred or
double vision (Table 3). Changes from baseline for each of these
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Fig 2. Median changes from baseline for
(A) hot flash scores and (B) hot flash
frequencies for the three study arms. bid,
twice per day.
Table 3. Worst Toxicity Data for the Individual Study Arms From the NCI CTCAE, Version 3.0 and the SED
Measure
Placebo
(n  62)
Pregabalin P
75 mg Twice a Day
(n  63)
150 mg Twice a Day
(n  66)
75 mg Twice a Day
v Placebo
150 mg Twice a Day
v Placebo
CTCAE
Dizziness, % .04 .0006
0-none 77 59 47
1-mild 15 32 36
2-moderate 8 10 12
3-severe 0 0 5
Cognitive troubles, % .87 .01
0-none 82 83 62
1-mild 11 16 24
2-moderate 6 2 14
SED
Concern about weight gain 1.0 1.0 2.0 .20 .002
Concern about sleepiness 1.0 1.0 2.0 .97 .049
Concern about dizziness 0.0 1.0 2.0 .054 .0001
Concern about coordination 0.0 0.0 1.0 .23 .008
Concern about concentration 0.0 1.0 1.0 .02 .006
Concern about blurred/double vision 0.0 0.0 1.0 .64 .005
NOTE. SED, based on a scale of 0 to 10 with 10 being worst toxicity, provides numbers representing the worst median changes from baseline during the
treatment period.
Abbreviations: NCI, National Cancer Institute; CTCAE, Common Terminology Criteria for Adverse Events; SED, symptom experience diary.
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symptoms are illustrated in Figure 3. Of the other symptoms queried
on the symptom experience diary (noted in Patients and Methods),
therewasnodifferencebetween theplaceboandeither of thepregaba-
lin treatments. Table 3 and Figure 3 illustrate that there was more
toxicity in the 150mg twice daily target dose arm than the 75mg twice
daily target dose arm and that some of the symptoms, after peaking,
tended to improve with time. Despite the above noted increase in
toxicity in the pregabalin arms, the dropout rates for toxicity were
statistically similar inall three studyarms(6, 3, and10patientsper arm
for the placebo, lower-dose, andhigher-dose pregabalin arms, respec-
tively), suggesting that the toxicity was relatively mild.
At study completion, patients were asked by study nurses, while
both parties were still blinded, whether they were satisfied with their
hot flash control and whether they thought the benefit of the treat-
ment was worth the toxicities that they attributed to it. Table 4 illus-
trates that the patients in the pregabalin treatment arms were much
more satisfied than patients in the placebo arm.
DISCUSSION
The results from this study support the prestudy primary hypoth-
esis that pregabalin at a target dose of 150 mg twice daily would
decrease hot flashes significantly more than would a placebo. The
findings also support that the lower 75mg twice daily target dose of
pregabalin decreases hot flashes to a degree similar to that of the
higher 150 mg twice daily target dose. Cross-study comparisons,
crude as they may be, suggest that the hot flash reduction observed
with pregabalin is comparable to that seenwith gabapentin15-18and
with newer antidepressant agents such as venlafaxine, desvenlafax-
ine, paroxetine, and citalopram.2-11 Each of these agents appears to
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Fig 3. Mean changes over time for each
study arm from the symptom experience
diary (scale of 0 to 10) for (A) undesirable
weight gain, (B) sleepiness, (C) dizziness,
(D) coordination difficulties, (E) trouble
concentrating, and (F) concerns regarding
blurred or double vision. Note that the
y-axis is magnified (scale of 0 to 3) to
illustrate differences between arms. bid,
twice per day.
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decrease hot flashes by approximately 20% to 30%more than does
a placebo.2
The higher pregabalin arm appeared to have significantly more
toxicity than did the placebo arm. Toxicity was less apparent in the
lower-dose pregabalin treatment arm.This, however, did not lead to a
significantly higher rate of patient dropout because of toxicity in the
pregabalin arms compared with the placebo arm.
Data from this trial lend support for the methodology used to
conduct it. Keeping inmind that both of the pregabalin arms received
identical doses of pregabalin for the first three treatment weeks as the
doses were being titrated upward, Figure 2 illustrates that the data
points for each of the two pregabalin treatment arms are remarkably
similar for these three treatment weeks. This supports that the num-
bersofpatients involved ineachstudyarmof this trial and thehotflash
daily diary and questionnaire that were used to measure hot flashes
represent validmeans of conducting clinical trials that examine treat-
ments to alleviate hot flashes. While some studies24-27 have suggested
that hotflash trials should includephysiologicmeasures of sweating as
ameans ofmeasuring hot flashes, hot flash daily diaries are an appro-
priate means of measuring hot flashes in patients participating in
clinical trials.28-30
The current trial required 28hot flashes perweek for study entry,
as opposed to previous Mayo Clinic/NCCTG hot flash trials, which
required 14 hot flashes per week.3,5,31-36 This requirement was made
because of concerns previously raised by some parties that 14 hot
flashes per week might be too few to study and because only approx-
imately 10% of patients in previous Mayo Clinic/NCCTG hot flash
trials had fewer than 28 hot flashes perweek so that accrual would not
be substantially affected.Of note, this concern about requiring amin-
imumof 14 hot flashes per week is not substantiated bywork that has
addressed this issue.21Unbeknownst to the authors of this studywhen
this study was developed, new data had demonstrated that placebo
effects aremore pronounced in studies where the number of baseline
hotflashes ishigher,37whichfitswith thehigherplaceboeffect thatwas
seen in this trial (approximately 50%) compared with similar previ-
ous trials.3,5,31-36
Although this trial did not includemenwith hot flashes, similar-
ities between hot flash treatment efficacies in women and men for
other agents,32,38 especially data that demonstrate that gabapentin
does decrease hot flashes in men to a degree similar to that in wom-
en,38 suggest that pregabalin might also be helpful for treating male
hot flashes related to androgen deprivation therapy.
Thus, in total, pregabalin at a target dose of 75 to 150 mg twice
daily appears to be a clinically useful means of treating hot flashes in
women. The lower dose appears to be as beneficial as the higher dose,
with less toxicity.
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